Measurement of ferritin in serum by radioimmunoassay

M. D. BARNETT, Y. B. GORDON1, J. A. L. AMESS, AND D. L. MOLLIN

From the Departments of Haematology and Reproductive Physiology1, The Medical College of St. Bartholomew’s Hospital, London EC1A 7BE, UK

SUMMARY A method for the measurement of circulating ferritin concentrations by direct radioimmunoassay is presented. The method described is simple to operate, precise, and sensitive and is suitable for the routine diagnostic measurement of ferritin in either plasma or serum.

Ferritin is the major intracellular iron storage protein found in the body, consisting of a spherical protein shell of MW 450,000 made up of 24 identical subunits. Iron is stored in the inner core as crystalline ferric-oxide-phosphate. Ferritin is found mainly in the reticuloendothelial system, predominantly in the spleen, liver, and bone marrow. Circulating levels of ferritin have been shown to reflect the total body iron stores in most clinical situations (Walters et al., 1973; Bentley and Williams, 1974) with the exception of familial varieties of haemochromatosis (Wands et al., 1976).

A number of sensitive radioisotopic assays have now been described for measuring ferritin in plasma or serum. All have been based on an immunoradiometric technique in which the antibody to ferritin is labelled with iodine-125 (Addison et al., 1972; Miles et al., 1974; Halliday et al., 1975). The major advantage of this immunoradiometric technique over previously described methods is that it is sensitive enough to measure normal circulating levels of ferritin. Unfortunately, like many immunoradiometric methods, this technique may be time-consuming and imprecise and show inter-assay variation in results. Recent radioimmunoassays have been described for use in man in which ferritin itself was labelled with $^{125}$I (Marcus and Zinberg, 1975; Luxton et al., 1977).

The present paper confirms and extends the use of direct radioimmunoassays for measuring ferritin in human serum or plasma. This technique is sufficiently sensitive to detect circulating levels within the normal range, it is easier to perform, and is more reproducible and economical than the immunoradiometric methods in current use.

Material and methods

REAGENTS

Phosphate buffered saline (PBS) 0·15 M phosphate buffer, pH 7·8, containing 9 g/l sodium chloride and 2 ppm sodium azide.

Assay diluent-PBS containing 1 mg/ml bovine serum albumin (Sigma RIA grade).

Donkey anti-rabbit serum (DARS) (RD 17, Wellcome Reagents Ltd, Beckenham, Kent).

Normal (inactivated) rabbit serum (NRS) (TC 69, Wellcome Reagents Ltd, Beckenham, Kent).

PREPARATION OF HUMAN LIVER FERRITIN

Human liver ferritin was prepared by a modification of the method of Aherne and Worwood (1974). Liver, obtained at necropsy from a patient with myocardial infarction, was homogenised, the mixture was heated to 70°C, and the supernatant was subjected to ammonium sulphate precipitation. The pellet obtained after high-speed centrifugation was dissolved in PBS and subjected to gel-filtration on a calibrated column of Agarose A5-m (Bio-rad Laboratories). The fractions containing a red-brown protein with a molecular weight corresponding to monomeric ferritin were pooled and concentrated by ultrafiltration.

The protein concentration of the ultrafiltrate was estimated by the method of Lowry et al. (1951). The purity was demonstrated by polyacrylamide disc gel electrophoresis using a 4% gel at pH 8·9, and the immunospecificity was demonstrated by two-dimensional immunoelectrophoresis (Clarke and Freeman, 1968) against antiferritin antiserum and against anti-whole human serum.

PREPARATION OF $^{125}$I-LABELLED FERRITIN

Human liver ferritin was iodinated by a modification

Received for publication 29 June 1977
Measurement of ferritin in serum by radioimmunoassay

of the technique described by Hunter and Greenwood (1962). Ten microgrammes of ferritin in 10 μl PBS and 10 μl of 0·4 m phosphate buffer, pH 7·4, was added to 1 mCi sodium $^{125}$I (Code No. IMS 30, Radiochemical Centre, Amersham) in a tapered polystyrene tube followed by 10 μl PBS containing 50 μg chloramine-T. After mixing for 30 seconds a further 20 μl PBS containing 60 μg sodium metabisulphite was added, followed by 100 μl assay diluent. The percentage incorporation of $^{125}$I into protein for each radioiodination was calculated using paper wick chromatography (Orskov, 1967). Five microlitres of the iodium reaction mixture was applied to a strip of Gelman paper (3-8 x 11). The wick was placed in a test tube containing 1 ml 5% trichloroacetic acid for 15 minutes. The paper was then cut into 1-cm strips, and the radioactivity was counted.

The iodination reaction mixture was purified by gel-filtration using an Agarose A5-m column eluted with assay diluent. The immunoreactivity of the labelled products in the column fractions was assessed by determining the percentage that was bound by an excess of antihuman ferritin antibody (Fig. 1). Fifty microlitres of each fraction was diluted in 1 ml assay diluent, and 100 μl of this was added to 100 μl of antiferritin antiserum to give a final antiserum dilution of 1:1000. After incubation for 2 h at 37°C the antibody bound and free protein were separated as described below. Control tubes containing no antiserum but the same concentration (1:1000) of normal serum (NRS) were included. The fractions containing the highest immunoreactivity were pooled, divided into aliquots, and stored at -20°C. The binding was assessed on each aliquot, after thawing, before use in the assay to assess the stability of the $^{125}$I-labelled ferritin; however, the final antiserum dilution was increased to $1.2 \times 10^6$ to correspond with the conditions used in the routine assay.

**SEPARATION OF BOUND AND FREE $^{125}$I-LABELLED PROTEIN**

The effect of using various concentrations of the different reagents was studied, and the suitability at each concentration was assessed using the criteria of Chard (1971). The incubation mixture in all the experiments contained 1 ng of $^{125}$I-labelled ferritin and a final dilution of antiferritin antibody of 1:1000 in a final volume of 500 μl. Control tubes containing no antibody but a similar concentration (1:1000) of normal rabbit sera (NRS) were included.

In the second antibody precipitation technique, varying concentrations of donkey anti-rabbit serum were added to each tube followed by varying concentrations of normal rabbit serum. After an incubation at 37°C for 2 h the reaction tubes were centrifuged at 2500 g for 30 min at 4°C; the supernatant was discarded and the precipitate containing the antibody-bound ferritin was counted.

For the fractional precipitation method, increasing volumes of ethanol or ammonium sulphate (Chard et al., 1971) or polyethylene glycol (6000) (Desbuquois and Aurbach, 1971) were used. In each case 50 μl horse gammaglobulin was added to provide a visible precipitate.

On the basis of these results the second antibody precipitation method was selected and used in all subsequent experiments.

**PRODUCTION AND ASSESSMENT OF ANTISERA**

Adult New Zealand White rabbits were immunised with the purified human liver ferritin. For both the initial and subsequent booster injections each rabbit received 500 μg of ferritin, prepared as a water-in-oil emulsion by mixing two volumes of
complete Freund's adjuvant (Difco Laboratories, Detroit, Michigan) with one volume of buffered ferritin. One millilitre of this emulsion was injected into multiple subcutaneous sites in the neck at intervals of four to seven weeks. Blood was obtained from an ear vein 28 days after primary immunisation and 14 days after boosting.

The antibody titre of the sera was assessed by measuring the binding to 125I-labelled ferritin. Antiserum dilution curves were constructed by setting up doubling dilutions of the antiserum to be tested in 450 μl assay diluent, followed by the addition of 50 μl of suitable dilution 125I-labelled ferritin (0.5-1 ng). The tubes were incubated for 18 h at 20°C before the addition of second antibody and a further incubation for 2 h at 37°C before final separation. Control tubes (diluent blanks) were set up without antiferritin antibody. The titre of the sera was defined as the dilution which bound 50% homologous labelled ferritin.

For the construction of standard curves, 50 μl of doubling dilutions of a standard unlabelled ferritin solution (2.5-350 μg/l) were added to 350 μl of the assay diluent followed by 50 μl of a suitable dilution of 125I-labelled ferritin (0.5-10 ng, 10 000 cpm) in assay diluent also containing 1:1000 normal rabbit sera and, finally 50 μl of specific antiserum diluted to give a final dilution ranging from 1 × 10^4 to 1 × 10^8. Control tubes were prepared as described above (diluent blank) as well as zero standards (no unlabelled ferritin). The tubes were incubated for 18 h at 4°C before the addition of second antibody and a further incubation of 2 h at 37°C before the final separation of bound and free 125I-labelled ferritin.

PREPARATION OF FERRITIN-FREE SERA
Ferritin-free human sera were prepared by immunoabsorption. Glutaraldehyde cross-linked rabbit antiferritin antibody was prepared according to the method of Avrameas and Ternynck (1969). The IgG fraction of rabbit antiferritin antiserum was suspended in 0.15 M NaCl and the pH was adjusted to 8.0 with 0.1 M NaOH. A 25% solution of glutaraldehyde was added to give a final concentration of 1 part protein: 10 parts glutaraldehyde, mixed, and left at room temperature for one hour. The conjugated protein was centrifuged, resuspended in 0.15 M NaCl, and washed. The conjugate was then added in excess to the serum, which had been trace labelled with 125I-labelled ferritin. The serum was mixed at 4°C for 48 h and centrifuged to remove the conjugated IgG-ferritin complex. The effectiveness of ferritin removal was assessed by measuring the concentration of ferritin and by counting the radioactivity before and after conjugation.

SUBJECTS STUDIED AND PROCEDURE
Sixty-five subjects were randomly selected from patients who had had a bone marrow biopsy as a part of a general haematological investigation. The group included patients with iron deficiency anaemia, megaloblastic anaemia, a combination of iron deficiency and megaloblastic anaemia, anaemia of chronic disorder, sideroblastic anaemia, and transfusional haemosiderosis. Patients with leukaemia or other neoplastic diseases were excluded from this series.

Haemoglobin concentration, packed cell volume, erythrocyte count, mean cell volume, mean cell haemoglobin, mean cell haemoglobin concentration, and leucocyte count were determined on sequestretated blood using a Coulter Counter model S, and the platelets were counted on a Technicon Auto-Analyzer.

Serum iron concentration was measured by an automated micromethod (Garry and Owen, 1967) using a Technicon AutoAnalyzer and the unsaturated iron binding capacity using a semiautomated micromethod with radioactive iron (Brozovic and Copestake, 1969). The measurement of serum and erythrocyte folate was carried out by a semiautomated microbiological assay using a chloramphenicol-resistant strain of Lactobacillus casei (Millbank et al., 1970). The vitamin B12 concentration was measured by a microbiological assay using Euglena gracilis Z strain (Anderson, 1964). Other haematological methods were those described by Dacie and Lewis (1975). Ferritin in serum was assayed in duplicate, as described above.

ASSESSMENT OF BONE MARROW IRON
Iron, which is stainable by the Prussian blue reaction, is present in the reticulum cells of the bone marrow fragments of normal individuals. The amount of this intracellular iron in the bone marrow fragments can be used as a guide to the state of the iron stores of the body (Gale et al., 1963). The amount of stainable iron in the fragments of the patients studied was assessed by one observer (JALA) without previous knowledge of the clinical and laboratory findings.

Stainable iron was graded as follows:

- Grade 0: no visible iron
- Grade 1+: small numbers of iron particles present in the reticulum cells of the marrow fragments
- Grade 2+: numerous small particles present in the reticulum cells throughout the marrow fragments with a tendency in some cases for the particles to aggregate into denser clumps
Measurement of ferritin in serum by radioimmunooassay

Grade 3+ dense, large deposits of iron in the reticulum cells of the marrow fragments.

Results

EVALUATION OF PURIFIED FERRITIN
The human liver ferritin, prepared by the method described above, appeared to be immunologically pure. Only a single peak was found when the material was subjected to two-dimensional immunoelectrophoresis against antiferritin antiserum and against anti-whole serum. The peak stained for both iron and protein. The material also appeared pure on polyacrylamide disc gel electrophoresis at pH 8.9, giving a single band which stained for protein running in the same position as a ferritin standard.

EVALUATION OF $^{125}$I-LABELLED FERRITIN
Two radioactive peaks were found when the iodination mixture was subjected to wick chromatography; one peak, the precipitated protein, remained at the origin. The second faster moving peak was found in a position identical with the single peak that was obtained when $^{125}$I was run alone. The mean percentage incorporation of $^{125}$I calculated from the results of wick chromatography was 33% (range 28-36%), and the mean specific activity of the labelled ferritin was 33 (range 28-36) $\mu$Ci/$\mu$g protein.

Chromatography of the iodination mixture on Agarose A5-m yielded three peaks of radioactivity (Fig. 1). Protein-bound radioactivity was confined to the first two peaks, as judged by the binding in antibody excess. The third peak was unreacted iodine. The first small peak of radioactivity showed high non-specific binding in the absence of antibody and probably represented aggregated material. The second, larger peak, however, demonstrated a low non-specific binding, and the maximum immunoreactivity occurred on the ascending limb of the peak. This probably represented intact monomeric ferritin, whereas in the descending portion of the peak degradation had probably taken place.

The $^{125}$I-labelled ferritin was stable for at least one month, as judged by its immunoreactivity. After this time there was a decrease in the binding of $^{125}$I-labelled ferritin with a concomitant rise in the non-specific binding (Fig. 2). Gel-filtration of the label stored at $-20^\circ$C for 60 days showed aggregation of the ferritin molecule, which accounted for the increase in non-specific binding, but the addition of disaggregating agents, storage at alternative temperatures, or freeze-drying did not enhance the stability of the preparation.

![Fig. 2](http://jcp.bmj.com/) Effect of storage at $-20^\circ$C on the binding of $^{125}$I-labelled ferritin and on the presence (—) and absence (——) of antibody.

SEPARATION OF ANTIBODY-BOUND AND FREE ANTIGEN
The double antibody technique proved an efficient method for the separation of bound and free antigen. Maximum binding of $^{125}$I-labelled ferritin was achieved after a 2-h second incubation at 37°C, by using a final dilution of 1:1000 normal rabbit serum and 1:80 donkey anti-rabbit serum. The other methods were less suitable, because both free and antibody-bound $^{125}$I-labelled ferritin were precipitated by the same concentrations of ammonium sulphate, ethanol, and PEG-6000.

FERRITIN-FREE SERUM
The results in the Table indicate that human ferritin

| Table Effect of ferritin removal by glutaraldehyde conjugated antiferritin antibody |
|-------------------------------|------------------|-------------------|
| Ferritin concentration (ug/l) | $^{125}$I added (cpm/l) |
| Pre-conjugation (a)*          | 10-0             | 2.92 x 10^4       |
|                                | 15-0             | 3.68 x 10^4       |
| Post-conjugation (a)          | < 5-0            | 0.24 x 10^4       |
|                                | < 5-0            | 0.29 x 10^4       |
| (b)                           |                  |                   |

*Two normal human sera (a, b) were used.
was removed by treating two human sera with glutaraldehyde-conjugated IgG specific to human ferritin. Ferritin could not be demonstrated by radioimmunoassay after such treatment, and less than 10% of the added radioactivity could be detected after immunoadsorption. Standard curves using both preparations of ferritin-free sera for the dilution of the standards were identical.

**EVALUATION OF ANTISERA AND SENSITIVITY OF ASSAY**

All rabbits developed antibodies, and in each case the titre rose after booster injections. The highest titres, defined as 50% binding with respect to homologous labelled ferritin, ranged from $2 \times 10^6$ to $2 \times 10^7$.

A series of standard curves was tested against varying dilutions of antiserum ranging from 1 in $1 \times 10^4$ to 1 in $1 \times 10^8$. When a final concentration of 1 in $2 \times 10^6$ antibody was used with labelled ferritin sufficient to give 10 000 cpm (0.5-I ng) and with a first incubation of 16 h at $4^\circ C$, the results of 10 consecutive assays (mean ± SD) showed a detection limit of 5 μg/l (Fig. 3). This dilution was used for the measurement of ferritin in serum in normal subjects with standards which ranged from 2.5 to 350 μg/l. If the circulating level of ferritin was above 350 μg/l the samples were further diluted in ferritin-free serum and reassayed.

Quality control sera were included in every assay for the assessment of inter-assay and intra-assay variation. The intra-assay coefficient of variation of sera with ferritin concentrations of 15, 40, and 56 μg/l, each assayed 10 times, were 8.0, 2.7, and 1.8%, respectively. The inter-assay coefficients of variation of four sera assayed in duplicate on 20 occasions with ferritin concentrations of 10, 33, 51, and 108 μg/l were 14, 6, 5, and 3%, respectively, over a six-month period.

Ten serum samples with starting values greater than 350 μg/l were subjected to a series of doubling dilutions in both buffer and ferritin-free serum. The dose response curves in both buffer and serum were parallel on visual inspection to those found when the purified ferritin standards were assayed. Six recovery experiments were performed by the addition of between 25 and 220 μg/l ferritin to the normal assay standards. The median recovery was 103% and the range was 88 to 122%.

**RELATIONSHIP BETWEEN SERUM FERRITIN AND IRON STATUS**

The 65 patients studied were classified into four groups according to the amount of iron present in their bone marrow using the following grades. Twenty-one patients were grade 0, eight patients were grade 1+, 29 were grade 2+, and the remaining seven were grade 3+. The ferritin levels in each group are shown in Figure 4.

There was a progressive increase in the serum ferritin levels between grade 0 and grade 3+ bone marrow iron stains, and although there was some overlap between grades 1+ and 2+ and between grades 2+ and 3+, no overlap existed when grade 0 was compared with either grade 1+ or 3+. The single patient in grade 2+ with a serum ferritin level less than 5 μg/l suffered from a pyrexia of unknown origin, and the discrepancy could not easily be explained.

**Discussion**

The present paper confirms and extends the use of a direct radioimmunoassay for the measurement of circulating levels of ferritin in human serum or plasma (Marcus and Zinberg, 1975; Luxton et al., 1977). However, the assay described here is considerably more sensitive than that described by Marcus and Zinberg (1975), and this is the first time that a comparison has been made between serum ferritin levels measured by direct radioimmunoassay and total body iron stores assessed by staining of the bone marrow.

A number of specific problems were encountered during the development of the radioimmunoassay. Firstly, in the preparation of human liver ferritin an Agarose gel chromatography step was essential to obtain monomeric ferritin. If this was not done
Measurement of ferritin in serum by radioimmunoassay

The addition of low concentrations of polyethylene glycol (Luxton et al., 1977). The preparation of highly specific and avid antisera presented no difficulty whatever, and the final dilution used in the routine assay was 1 in $2 \times 10^4$.

Serum ferritin in normal individuals is heterogeneous and contains isoferritins characteristic of both liver and spleen apoferritin (Drysdale et al., 1977). The method described uses human liver as a source of ferritin for the tracer and standards, and in the production of antibodies. We have assumed, on the basis of the work of Drysdale and others, that splenic tissues could have been used as the source of ferritin.

In the patients studied, this assay showed that there was a good correlation between serum ferritin levels and stainable bone marrow iron. This has previously been described using an immunoradiometric method for the measurement of serum ferritin (Bentley and Williams, 1974; Hussein et al., 1975). The data presented suggest that the direct radioimmunoassay provided a reliable, precise, and robust method for the estimation of circulating levels of ferritin for use in the diagnosis of iron deficiency.

We thank Dr B. Brozovic for his invaluable encouragement and discussion, the staff of the diagnostic haematology laboratory who carried out haematological investigations of the subjects studied, and the Wellcome Trust for their financial support for this project.

Part of the data presented in this paper with a description of the method was first given at an Iron Club Meeting held at the Université Catholique de Louvain, Louvain-la-Neuve, Belgium, in April 1976.

References


Bentley, D. P., and Williams, P. (1974). Serum ferritin concentration as an index of storage iron in rheu-

Fig. 4 Serum ferritin levels (●) in patients with a variety of bone marrow iron grades. The lower limit of detection of the assay is 5 µg/l.
matoid arthritis. *Journal of Clinical Pathology,* 27, 786-788.


Requests for reprints to: Miss Myra D. Barnett, Department of Haematology, St. Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK.
Measurement of ferritin in serum by radioimmunoassay.

M D Barnett, Y B Gordon, J A Amess and D L Mollin

*J Clin Pathol* 1978 31: 742-748
doi: 10.1136/jcp.31.8.742

Updated information and services can be found at:
http://jcp.bmj.com/content/31/8/742

**Email alerting service**

Receive free email alerts when new articles cite this online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/